Skip Navigation

European Heart Journal 1994 15(8):1050-1056;
Copyright © 1994 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by HEUSCH, A.
Right arrow Articles by BOURGEOIS, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HEUSCH, A.
Right arrow Articles by BOURGEOIS, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 The European Society of Cardiology

Clinical experience with propafenone for cardiac arrhythmias in the young

A. HEUSCH, H. H. KRAMER*, O. N. KROGMANN, S. RAMMOS and M. BOURGEOIS

Departments of Pediatric Cardiology, Heinrich-Heine-University Düsseldorf
*Christian-Albrechts-University Kiel, Germany

Received 3 September 1993; revised 9 March 1994; .

Correspondence Andreas Heusch, MD, Department of Pediatric Cardiology, Heinrich-Heine-University, Moorenstr. 5, PB: 101007, D-40001 Düsseldorf, Germany.

Abstract

Seventy-two children were treated with propafenone between 1980 and 1990. The mean age was 34 months (range 0.192). Arrhythmias included atrioventricular re-entry tachycardia in 32 patients (44%), atrial flutter in 16 (22%), atrial or junctional ectopic tachycardia in 10 (14%), atrial re-entry tachycardias in three (4%) and ventricular arrhythmias in 11 patients (16%). The efficacy of oral treatment was good in patients with atrio-ventricular re-entry tachycardia (80%), atrial flutter (71%) and atrial ectopic tachycardia (83%); it was poor in ventricular arrhythmias (40%).

The mean oral dose was 13.5 mg. kg–1. day–1. Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not. No correlation between dosage and serum level was observed. Intravenous propafenone administration was only partially successful in suppressing supraventricular tachycardias (6 of 11 patients).

The presence of a congenital heart defect and the time of onset of the arrhythmias had a significant influence on the efficacy of propafenone. Better results were observed in patients with normal hearts and in whom onset of arrhythmia was pre-natal (success 80%) as well as in patients with arrhythmias seen early after surgery for congenital heart defects (success 87%). Success (65%) was also observed in patients without congenital heart defects and postnatal onset of supraventricular arrhythmias. Patients with ventricular or supraventricular arrhythmias late after corrective surgery showed the poorest response (31%).

Key Words: Propafenone • arrhythmias in children • antiarrhythmic treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
P. F. Kirchhof, C. L. Fabritz, and M. R. Franz
Postrepolarization Refractoriness Versus Conduction Slowing Caused by Class I Antiarrhythmic Drugs : Antiarrhythmic and Proarrhythmic Effects
Circulation, June 30, 1998; 97(25): 2567 - 2574.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.